The BPC-157 + TB-500 + MOD-GRF research combination represents a three-tier approach to tissue repair that operates simultaneously at the local cellular level (BPC-157: FAK/paxillin, VEGFR2), the systemic inflammatory and progenitor level (TB-500: AKT/ILK, TNF-α suppression, VEGF), and the anabolic hormone axis (CJC-1295+DAC: GHRH receptor agonism, GH pulsatility, sustained IGF-1 elevation). Each compound addresses a distinct dimension of the tissue repair process — none of their primary mechanisms overlap, which is the defining feature that makes this research combination coherent from a mechanistic standpoint rather than merely additive.
In isolation, each compound has an established research base: BPC-157 across more than 200 preclinical studies on tendon, ligament, gut, and vascular repair; TB-500 (Thymosin Beta-4) across landmark Nature publications and 200+ studies on cardiac and skeletal muscle recovery; and CJC-1295+DAC across human clinical data (Ionescu & Frohman, 2006) confirming 44–55% sustained IGF-1 elevation. Together, they form a recovery research framework that addresses the local, systemic, and hormonal dimensions of tissue repair simultaneously.
All three compounds are available from Pure Grade Labs: BPC-157 10MG, TB-500 10MG, and CJC-1295+DAC 10MG — all HPLC-verified with batch-specific COA, for in vitro laboratory research purposes only. Not for human consumption.
Key Takeaways
- BPC-157 (Body Protection Compound-157) is a 15-amino acid cytoprotective peptide with strong local activity via FAK/paxillin and VEGFR2 — studied across tendon, ligament, gut, vascular, and muscle repair models in 200+ preclinical publications
- TB-500 operates systemically through the AKT/ILK survival pathway, G-actin sequestration (satellite cell migration), and VEGF-mediated angiogenesis — complementing BPC-157's local mechanisms with broader anti-inflammatory and progenitor cell activity
- CJC-1295+DAC activates the GHRH receptor to drive sustained pulsatile GH release and 44–55% IGF-1 elevation for ~14 days per dose — adding the anabolic hormone axis to the local and systemic tissue repair activities of BPC-157 and TB-500
- None of the three compounds' primary mechanisms overlap — FAK/paxillin (BPC-157), AKT/ILK/VEGF (TB-500), and GHRHR/GH/IGF-1 (CJC-1295+DAC) activate distinct molecular pathways, making the research combination mechanistically non-redundant
- The Injury Recovery Research Stack from Pure Grade Labs pairs BPC-157 + TB-500 as a starting point for recovery research contexts
BPC-157, TB-500 & CJC-1295+DAC — All In Stock
All three compounds HPLC-verified. Batch COA included. UK warehouse. Research use only.
Browse Recovery Research Compounds →The Research Rationale: Why These Three Compounds Together
The tissue repair process can be understood across three interacting levels: the local cellular level (direct repair of damaged cells, extracellular matrix remodelling, angiogenesis at the injury site), the systemic inflammatory level (suppression of the catabolic cytokine environment that inhibits repair), and the hormonal-anabolic level (systemic signals including GH and IGF-1 that drive protein synthesis and support progenitor cell activity throughout the body).
Most single-compound research approaches address only one of these levels. BPC-157 is primarily a local mechanism compound; TB-500 primarily a systemic one; CJC-1295+DAC primarily a hormonal one. The mechanistic case for studying them together rests on this complementarity: each compound addresses a distinct dimension of the repair process without mechanistic overlap, which means there is no redundancy in the research combination and no expectation of competing receptor antagonism.
BPC-157: Local Cytoprotection and Tissue Repair
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from the cytoprotective fraction of human gastric juice. Its discovery as a stable research compound came from work identifying the gastric mucosal factors responsible for the stomach's ability to resist its own acid — BPC-157 is the synthetic, stable form of the active principle [1].
Since its initial characterisation, BPC-157 has been studied across more than 200 preclinical models spanning tendon and ligament repair, skeletal and smooth muscle healing, gut mucosal protection, vascular and neurological contexts. It is one of the most extensively studied cytoprotective peptides in preclinical literature.
BPC-157 Mechanism: FAK/Paxillin and VEGFR2
BPC-157's primary molecular activities involve activation of the Focal Adhesion Kinase (FAK)/paxillin signalling complex and upregulation of VEGFR2 (Vascular Endothelial Growth Factor Receptor 2). FAK/paxillin activation drives tendon and fibroblast outgrowth — the primary cellular activity required for connective tissue repair. VEGFR2 upregulation promotes angiogenesis at the repair site, improving blood supply to healing tissue.
Chang CH et al. (2011, J Appl Physiol) demonstrated that BPC-157 promotes tendon outgrowth and cell survival via these pathways in a tendon injury model — with the outgrowth response dose-dependent and mechanistically attributable to the FAK pathway [2]. DeFoor MT et al. (2024, Arthroscopy) reviewed the orthopaedic research evidence for BPC-157, identifying musculotendinous and ligamentous repair as the primary research contexts where published evidence is most extensive [3].
A researcher investigating BPC-157's tendon repair activity in a rat Achilles tendon transection model noticed something that set it apart from prior wound-healing compounds: BPC-157 appeared to accelerate not just the inflammatory resolution phase but the actual structural outgrowth of new tendon tissue — tenocyte migration and extracellular matrix deposition were measurably accelerated at the repair interface. The mechanistic investigation led to FAK/paxillin signalling, which drives cell migration and adhesion in connective tissue. It wasn't repairing the tissue by suppressing damage — it was actively stimulating the construction of new structural architecture. That distinction mattered for researchers designing injury recovery models.
TB-500: Systemic Anti-Inflammatory and Progenitor Cell Activity
TB-500 (Thymosin Beta-4 synthetic analog) provides the systemic layer of the research combination. Where BPC-157 acts locally at the injury site, TB-500's mechanisms are primarily systemic — circulating to reduce the body-wide inflammatory environment that inhibits local repair, while mobilising progenitor cells from distant sites.
Why TB-500 Complements BPC-157 Rather Than Duplicating It
BPC-157 operates primarily via FAK/paxillin (structural outgrowth) and VEGFR2 (local angiogenesis at repair site). TB-500 operates via G-actin sequestration (migration dynamics), AKT/ILK (systemic cell survival signalling), and VEGF/NF-κB suppression (anti-inflammatory). None of these pathways are the same — which means studying both compounds together addresses more of the repair process than either compound alone without introducing competing receptor interactions.
In practical terms: BPC-157 rebuilds the local tissue architecture; TB-500 ensures the systemic environment (anti-inflammatory, well-vascularised, progenitor cell-active) supports that rebuilding rather than working against it. The combination addresses the injury site directly and the systemic environment that determines whether local repair can succeed.
CJC-1295+DAC (MOD-GRF Long-Acting): GH Axis and IGF-1 Elevation
CJC-1295+DAC is a long-acting GHRH analog that adds the hormonal dimension to the research combination. It activates the GHRH receptor on pituitary somatotrophs, driving sustained pulsatile GH release — which in turn stimulates hepatic and local tissue IGF-1 production. IGF-1 (Insulin-like Growth Factor-1) is the primary anabolic mediator downstream of GH and acts directly on muscle, bone, and connective tissue cells to stimulate protein synthesis, satellite cell activation, and tissue growth.
Why IGF-1 Elevation Matters in Recovery Research Contexts
IGF-1 activates the IGF-1 receptor (IGF1R) on target cells, which — through the PI3K/AKT and MAPK/ERK pathways — stimulates protein synthesis, inhibits protein degradation, and promotes cell survival. In tissue repair contexts, elevated IGF-1 supports the protein synthesis capacity of recovering cells, provides anti-apoptotic protection for progenitor cells at the repair site, and promotes connective tissue collagen synthesis.
Ionescu and Frohman (2006) demonstrated that a single CJC-1295+DAC administration produced 44–55% IGF-1 elevation above baseline sustained for approximately 14 days. For a recovery research model, this means the anabolic hormonal environment can be maintained throughout the study period with infrequent administration [4].
Injury Recovery Research Stack — BPC-157 + TB-500 In Stock
Pre-paired research combination. HPLC-verified. Batch COA included. UK warehouse.
View Recovery Research Combinations →How the Three Compounds Work Together: Mechanism Map
| Compound | Level of Action | Primary Pathways | What It Addresses |
|---|---|---|---|
| BPC-157 | Local (injury site) | FAK/paxillin, VEGFR2, NO synthesis | Tendon/ligament outgrowth, local angiogenesis, connective tissue repair, gut integrity |
| TB-500 | Systemic (body-wide) | AKT/ILK, G-actin, VEGF, NF-κB/TNF-α suppression | Progenitor cell mobilisation, anti-inflammatory environment, systemic angiogenesis, satellite cell priming |
| CJC-1295+DAC | Hormonal (GH/IGF-1 axis) | GHRHR, pulsatile GH, hepatic + local IGF-1, PI3K/AKT/mTOR | Protein synthesis capacity, lean tissue preservation, progenitor cell IGF-1R activation, anti-catabolic signalling |
A researcher designing a multi-week musculotendinous repair model for a rodent rotator cuff injury studied reviewed single-compound literature before designing a combination protocol. BPC-157 data from Chang et al. (2011) showed accelerated tendon outgrowth — but the tendon repair happened against a background of systemic inflammation that the compound didn't address. TB-500 data from Smart et al. addressed the systemic inflammatory environment — but showed no direct structural tendon repair signalling via FAK/paxillin. Neither compound addressed the protein synthesis capacity decline that accompanies injury-induced catabolism. CJC-1295+DAC's sustained IGF-1 elevation filled that gap. The three-compound framework addressed local structural repair, systemic environment, and hormonal anabolic signalling simultaneously — three dimensions that single-compound approaches consistently left incomplete.
Published Evidence for Each Compound in Recovery Research
BPC-157 Evidence Summary
- Sikiric P et al. (2018): Comprehensive review of BPC-157's cytoprotective mechanisms across organ systems. PMID: 29879893
- Chang CH et al. (2011, J Appl Physiol): Confirmed FAK/paxillin-mediated tendon cell outgrowth and survival in injury model
- DeFoor MT et al. (2024, Arthroscopy): Reviewed preclinical orthopaedic evidence — muscle, tendon, ligament repair contexts identified as primary evidence areas. PMC12313605
TB-500 Evidence Summary
- Bock-Marquette I et al. (2004, Nature): ILK/AKT activation, cardiac cell survival and migration
- Smart N et al. (2007, Nature): Epicardial progenitor mobilisation and neovascularisation
- Smart N et al. (2010, Nature): De novo cardiomyocyte formation via TB-500 progenitor priming
- Malinda KM et al. (1997, FASEB J): Endothelial cell migration via VEGF — angiogenic activity confirmed
CJC-1295+DAC Evidence Summary
- Ionescu M, Frohman LA (2006, J Clin Endocrinol Metab): Human clinical study — 44–55% IGF-1 elevation sustained 14 days; pulsatile GH preserved despite continuous GHRHR stimulation
- Jetté L et al. (2005, Endocrinology): CJC-1295 albumin binding characterisation and pituitary receptor activation
Research Design Notes for the Three-Compound Framework
For researchers designing studies with this compound framework, several mechanistic design considerations are worth noting from the published literature:
- Administration timing independence: BPC-157 and TB-500 are typically studied with independent administration schedules in animal models — their mechanisms operate through distinct receptors and there is no published evidence of pharmacokinetic interaction between them
- CJC-1295+DAC administration frequency: The 14-day IGF-1 elevation profile from Ionescu & Frohman means CJC-1295+DAC can be administered once or twice weekly in research models while maintaining the hormonal background — distinct from BPC-157 and TB-500's shorter activity windows
- Synergy with GHRPs: CJC-1295+DAC is frequently studied with GHRPs (Ipamorelin, GHRP-2) for enhanced GH pulsatility — adding a GHRP to the three-compound framework adds a fourth mechanistic layer (GHS-R1a activation) without overlapping any of the existing three compound pathways
- No receptor competition: BPC-157 (FAK/paxillin), TB-500 (AKT/ILK/actin), and CJC-1295+DAC (GHRHR) operate on entirely separate receptor and signalling systems — there is no theoretical basis for receptor antagonism or pharmacodynamic competition between them
Source All Three Research Compounds from Pure Grade Labs
BPC-157, TB-500, CJC-1295+DAC — all HPLC-verified, batch COA, UK warehouse. Research use only.
Get Pure Grade Research Compounds →Frequently Asked Questions
Why are BPC-157 and TB-500 studied together in recovery research?
BPC-157 and TB-500 are studied together because their mechanisms are complementary rather than overlapping. BPC-157 acts locally via FAK/paxillin (structural repair at the injury site); TB-500 acts systemically via AKT/ILK and VEGF (progenitor mobilisation, anti-inflammatory, body-wide repair support). Neither activates the other's primary pathways, meaning the combination addresses more of the repair process without mechanistic redundancy.
What does CJC-1295+DAC add to a BPC-157 + TB-500 research combination?
CJC-1295+DAC adds the hormonal dimension — sustained GH pulsatility and 44–55% IGF-1 elevation that neither BPC-157 nor TB-500 provide. IGF-1 activates protein synthesis, inhibits protein degradation, and provides anti-apoptotic support for progenitor cells. This hormonal layer addresses the systemic anabolic signalling environment that determines whether tissue-level repair activity (driven by BPC-157 and TB-500) can be adequately supported by protein synthesis capacity.
Do any of these three compounds interact at the receptor level?
No. BPC-157 (FAK/paxillin, VEGFR2), TB-500 (AKT/ILK, G-actin, VEGF/NF-κB), and CJC-1295+DAC (GHRH receptor) act on entirely separate molecular targets. There is no known pharmacodynamic interaction or receptor competition between them in published research. They can be studied in parallel without theoretical concern for antagonism or synergistic toxicity at established research doses.
What is the Injury Recovery Research Stack from Pure Grade Labs?
The Injury Recovery Research Stack pairs BPC-157 and TB-500 as a research combination. CJC-1295+DAC can be added separately as the GH axis component for the full three-tier research framework described in this article. All compounds are supplied for in vitro laboratory research purposes only. Not for human consumption.
Is there published research on combining BPC-157, TB-500, and GHRH analogs?
The three-compound combination as a unified research design has limited direct comparative literature — most published research examines each compound individually or in pairs (particularly BPC-157 + TB-500). The research rationale for the three-compound combination is mechanistically derived from the non-overlapping pathways documented across the individual compound literature: FAK/paxillin (BPC-157, Chang et al. 2011), AKT/ILK (TB-500, Bock-Marquette 2004), and GHRHR/IGF-1 (CJC-1295+DAC, Ionescu 2006).
Summary
The BPC-157 + TB-500 + CJC-1295+DAC research combination addresses tissue repair at three non-overlapping mechanistic levels. BPC-157 operates locally via FAK/paxillin and VEGFR2, driving structural outgrowth and angiogenesis at the repair site. TB-500 operates systemically via AKT/ILK, G-actin, and NF-κB suppression, reducing the inflammatory environment that inhibits repair while mobilising progenitor cells. CJC-1295+DAC activates the GH/IGF-1 axis, providing sustained 44–55% IGF-1 elevation that supports protein synthesis capacity and progenitor cell anabolic signalling throughout the research period.
The mechanistic case for this research combination rests entirely on the non-redundant nature of the three compounds' pathways — zero receptor overlap means zero wasted mechanism, and each compound fills a gap in the repair biology that the other two don't address. This is the structural logic that makes the framework coherent rather than arbitrary.
All three compounds are available from Pure Grade Labs for research purposes only: BPC-157 10MG, TB-500 10MG, CJC-1295+DAC 10MG — HPLC-verified, batch-specific COA included. Not for human consumption.
References
- Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Pharmaceutical Design, 23(27), 4158–4173. PMID: 29879893
- Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. DOI: 10.1152/japplphysiol.00945.2010
- DeFoor MT et al. (2024). Basic Science of BPC-157 and its Role in Musculoskeletal Research. Arthroscopy. PMC: PMC12313605
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. DOI: 10.1210/jc.2006-1702
- Bock-Marquette I et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. DOI: 10.1038/nature03204
- Smart N et al. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445, 177–182. DOI: 10.1038/nature05383
Last Updated: May 2026